No products in the cart.
Triptorelin is a gonadotropin-releasing hormone agonist (GnRH agonist). It’s used as an acetate. It is a man-made form of a hormone responsible for regulating many body processes. It’s a decapeptide that causes constant stimulation in the pituitary gland, which decreases the secretion of gonadotropins: luteinizing hormone (LH) and follicle stimulating hormone (FSH). Triptorelin overstimulates the body’s production of hormones and then it causes production to shut down entirely for a short period of time. In medicine, it is used in the treatment of prostate cancer through an injection, and marketed under the brand names Diphereline, Decapeptyl, and Gonapeptyl. It treats the symptoms of prostate cancer, not the cancer itself. When used for treating prostate cancer, patients sometimes indicate an increase or worsening symptoms for the first few weeks as Triptorelin increases testosterone levels, but most patients report symptom relief after the first dose.
Clinical Studies of Triptorelin
A multi-center clinical trial of triptorelin was organized to evaluate the use of triptorelin and adverse effects of using triptorelin injections monthly for the treatment of endometriosis. Endometriosis is a chronic disease that affects over 6 million females in the United States. Endometriosis is when the tissues lining the uterus grow in other areas outside of the uterus, in the abdomen or on the ovaries, or on the fallopian tubes or the area between the vagina and rectum, for example. Less commonly, the misplaced tissue can growth in the lung, arm or other locations.